CHRS vs. CMPX, GRTS, KOD, PSTX, OCGN, AURA, SLDB, FENC, SOPH, and BDTX
Should you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include Compass Therapeutics (CMPX), Gritstone bio (GRTS), Kodiak Sciences (KOD), Poseida Therapeutics (PSTX), Ocugen (OCGN), Aura Biosciences (AURA), Solid Biosciences (SLDB), Fennec Pharmaceuticals (FENC), SOPHiA GENETICS (SOPH), and Black Diamond Therapeutics (BDTX). These companies are all part of the "biological products, except diagnostic" industry.
Coherus BioSciences (NASDAQ:CHRS) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and community ranking.
Compass Therapeutics has a net margin of 0.00% compared to Coherus BioSciences' net margin of -92.48%. Coherus BioSciences' return on equity of 0.00% beat Compass Therapeutics' return on equity.
Compass Therapeutics has lower revenue, but higher earnings than Coherus BioSciences. Compass Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.
72.8% of Coherus BioSciences shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 11.0% of Coherus BioSciences shares are owned by insiders. Comparatively, 30.0% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Coherus BioSciences received 412 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 70.97% of users gave Compass Therapeutics an outperform vote while only 64.97% of users gave Coherus BioSciences an outperform vote.
Coherus BioSciences has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.
Coherus BioSciences currently has a consensus target price of $9.29, suggesting a potential upside of 288.52%. Compass Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 354.55%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Coherus BioSciences.
In the previous week, Compass Therapeutics had 6 more articles in the media than Coherus BioSciences. MarketBeat recorded 8 mentions for Compass Therapeutics and 2 mentions for Coherus BioSciences. Compass Therapeutics' average media sentiment score of 0.29 beat Coherus BioSciences' score of 0.18 indicating that Compass Therapeutics is being referred to more favorably in the news media.
Summary
Compass Therapeutics beats Coherus BioSciences on 11 of the 17 factors compared between the two stocks.
Get Coherus BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Coherus BioSciences Competitors List
Related Companies and Tools